
CLAIMS

1. Compound of formula (I)



(I)

in which:

A may be $-X_1-$ or $-X_1-OC(R_9)(R_{10})-$, in which

X_1 may be an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and

R_9 and R_{10}, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

Y is OH

R_1 and R_2, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

R_3, R_4 and R_8, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", -CN, -CONR'R", $-SO_2NR'R"$, $-SO_2R'$, nitro and trifluoromethyl; with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_5 may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", nitro and trifluoromethyl, or R_5 together with one from among R_6 and R_7 forms a ring having 5 or 6 carbon atoms; with R' and R", which may be identical or different each other, represented by hydrogen and

an alkyl group having from 1 to 5 carbon atoms,

R_6 and R_7, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, or together form a group C=O, or one from among R_6 and R_7, together with R_5, forms a ring having 5 or 6 carbon atoms,

with the proviso that when Y is -OH, A is different from an alkyl group having 1 carbon atom, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms, or alternatively at least one of the groups from R_1 to R_8 is different from hydrogen.

2. Compound according to Claim 1, characterized in that X_1 is an alkyl group having from 1 to 3 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 3 carbon atoms or one or more alkoxy groups having 1 or 2 carbon atoms.

3. Compound according to Claim 1, characterized in that X_1 is chosen from the group comprising a group CH_2, a group CH_2CH_2 or a group $C(CH_3)_2$, and R_9 and R_{10}, which may be identical or different each other, are hydrogen or a CH_3 group.

4. Compound according to Claim 1, characterized in that residue A is chosen from the group comprising a group CH_2, a group CH_2CH_2, a group $C(CH_3)_2$, a group $CH_2CH_2OCH_2$, a group $CH_2CH_2OC(CH_3)_2$ and a group $CH_2CH_2CH_2OC(CH_3)_2$.

5. Compound according to Claim 1, characterized in that R_3, R_4 and R_8, which may be identical or different each other, are chosen from the group comprising a hydrogen atom, an alkyl group having from 1 to 3 carbon atoms, an alkoxy group having 1 or 2 carbon atoms, a Br, Cl or F atom, an OH group, a nitro group, a trifluoromethyl group or a group N(R')(R") or -N(R')COR", -CN, -CONR'R", $-SO_2NR'R"$, $-SO_2R'$, with R' and R", which may be identical or different each other, represented by a hydrogen atom and an alkyl group having from 1 to 3 carbon atoms.

6. Compound according to Claim 1, characterized in that R_5 is chosen from the group comprising a hydrogen atom, an alkyl group having from 1 to 3 carbon atoms, an alkoxy group having 1 or 2 carbon atoms, a halogen atom, an OH group, or R_5, together with one from among R_6 and R_7, forms a ring having 5 or 6 carbon atoms.

7. Compound according to Claim 1, characterized in that R_6 and R_7, which may be identical or different each other, are chosen from the group comprising a hydrogen atom, an alkyl group having from 1 to 3 carbon atoms, or together form a group C=O, or one from among R_6 and R_7, together with R_5, forms a ring having 5 or 6 carbon atoms.

8. Pharmaceutical composition comprising the compound of formula (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, ester or prodrug thereof, and at least one pharmaceutically acceptable vehicle.

9. Pharmaceutical composition according to Claim 8, characterized in that the said pharmaceutically acceptable salt is an addition salt with physiologically acceptable organic or mineral acids or bases.

10. Pharmaceutical composition according to Claim 9, characterized in that the said physiologically acceptable acids are chosen from the group comprising hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, ascorbic acid, benzoic acid, citric acid, fumaric acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-toluenesulfonic acid, benzenesulfonic acid, succinic acid, tannic acid and tartaric acid.

11. Pharmaceutical composition according to Claim 9, characterized in that the said physiologically acceptable bases are chosen from the group comprising ammonium hydroxide, calcium hydroxide, magnesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine,


N-ethylmorpholine, N-ethylpiperidine, N-methylglucamine, glucamine, glucosamine, histidine, N-(2-hydroxyethyl)piperidine, N-(2-hydroxyethyl)pyrrolidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, theobromine, triethylamine, trimethylamine, tripropylamine and tromethamine.

12. Pharmaceutical composition according to Claim 8, characterized in that the said pharmaceutically acceptable ester is formed with physiologically acceptable organic acids or alcohols.

13. Pharmaceutical composition according to any one of Claims 8 to 12, characterized in that the said composition contains a stereoisomer or an enantiomer of the compound of formula (I), or a pharmaceutically acceptable salt, ester or prodrug thereof, or a mixture thereof.

14. Pharmaceutical composition according to any one of Claims 8 to 13, characterized in that the said pharmaceutically acceptable vehicle is chosen from the group comprising glidants, binders, disintegrants, fillers, diluents, flavourings, colorants, fluidizers, lubricants, preserving agents, humectants, absorbents and sweeteners.

15. Use of a compound of formula (I)



(I)

in which:

A may be $-X_1-$ or $-X_1-OC(R_9)(R_{10})-$, in which

X_1 may be an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon

atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and

R_9 and R_{10}, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

Y is OH,

R_1 and R_2, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,


R_3, R_4 and R_8, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", -CN, -CONR'R", $-SO_2NR'R"$, $-SO_2R'$, nitro and trifluoromethyl; with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_5 may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", nitro and trifluoromethyl, or R_5 together with one from among R_6 and R_7 forms a ring having 5 or 6 carbon atoms; with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_6 and R_7, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, or together form a group C=O, or one from among R_6 and R_7, together with R_5, forms a ring having 5 or 6 carbon atoms,

for the preparation of a pharmaceutical composition for treating diseases based on the expression of CX3CR1 and p40 selected from the group comprising lupus nephritis, diabetic nephropathy, Crohn's disease, ulcerative colitis, coronary disorders, restenosis, myocardial infarction, angina, chronic degenerative inflammatory diseases, psoriasis, type II diabetes, tumours, and cancer.

16. Use of a compound of formula (I)



(I)

in which:

A may be $-X_1-$ or $-X_1-OC(R_9)(R_{10})-$, in which

X_1 may be an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and

R_9 and R_{10}, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

Y is OH,

R_1 and R_2, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

R_3, R_4 and R_8, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", -CN, -CONR'R", $-SO_2NR'R"$, $-SO_2R'$, nitro and trifluoromethyl; with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_5 may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", nitro and trifluoromethyl, or R_5 together with one from among R_6 and R_7 forms a ring having 5 or 6 carbon atoms; with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_6 and R_7, which may be identical or different each other, may be

hydrogen, an alkyl group having from 1 to 5 carbon atoms, or together form a group C=O, or one from among R_6 and R_7, together with R_5, forms a ring having 5 or 6 carbon atoms,

with the proviso that when Y is -OH, A is different from an alkyl group having 1 carbon atom, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms, or alternatively at least one of the groups from R_1 to R_8 is different from hydrogen,

for the preparation of a pharmaceutical composition for treating diseases based on the expression of MCP-1, CX3CR1 and p40.

17. Use according to Claim 16, characterized in that the said diseases based on the expression of MCP-1 and CX3CR1 are chosen from the group comprising articular diseases, renal diseases, cardiovascular diseases, metabolic syndrome, obesity, diabetes, insulin resistance and cancer.

18. Use according to Claim 16, characterized in that the said diseases based on the expression of MCP-1 are chosen from the group comprising rheumatoid arthritis, arthritis induced by viral infections, psoriatic arthritis, arthrosis, lupus nephritis, diabetic nephropathy, glomerulonephritis, polycystic kidney disease, interstitial lung disease, fibrosis, multiple sclerosis, Alzheimer's disease, HIV-associated dementia, atopic dermatitis, psoriasis, vasculitis, restenosis, atherosclerosis, myocardial infarction, angina, acute coronary diseases, adenomas, carcinomas and metastases, metabolic diseases and complications following surgical interventions.


19. Use according to Claim 16, characterized in that the said diseases based on the expression of CX3CR1 are chosen from the group comprising rheumatoid arthritis, lupus nephritis, diabetic nephropathy, Crohn's disease, ulcerative colitis, coronary disorders, restenosis, atherosclerosis, myocardial infarction, angina, and complications following surgical interventions.

20. Use according to Claim 16, characterized in that the said diseases based on the expression of p40 are chosen from the group comprising autoimmune diseases, chronic degenerative inflammatory diseases, and

cancer.

21. Use according to Claim 16, characterized in that the said diseases based on the expression of p40 are chosen from the group comprising rheumatoid arthritis, psoriasis, glomerulonephritis, diabetes, lupus erythematosus, diabetes, Crohn's disease, and tumours.

22. Method for treating or preventing diseases based on the expression of CX3CR1 and p40, selected from the group comprising lupus nephritis, diabetic nephropathy, Crohn's disease, ulcerative colitis, coronary disorders, restenosis, myocardial infarction, angina, chronic degenerative inflammatory diseases, psoriasis, type II diabetes, tumours, and cancer, characterized by the administration to a person in need thereof of an effective amount of a compound of formula (I):



(I)

in which:

A may be $-X_1-$ or $-X_1-OC(R_9)(R_{10})-$, in which

X_1 may be an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and

R_9 and R_{10}, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

Y is OH,

R_1 and R_2, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group


having from 1 to 3 carbon atoms,

R_3, R_4 and R_8, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", -CN, -CONR'R", -SO_2NR'R", -SO_2R', nitro and trifluoromethyl; with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_5 may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", nitro and trifluoromethyl, or R_5 together with one from among R_6 and R_7 forms a ring having 5 or 6 carbon atoms; with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms, and

R_6 and R_7, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, or together form a group C=O, or one from among R_6 and R_7, together with R_5, forms a ring having 5 or 6 carbon atoms.

23. Method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40, characterized by the administration to a person in need thereof of an effective amount of a compound of formula (I):



(I)

in which:

A may be -X_1- or -X_1-OC(R_9)(R_{10})-, in which

X_1 may be an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms,

and

R_9 and R_{10}, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

Y is OH

R_1 and R_2, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

R_3, R_4 and R_8, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", -CN, -CONR'R", -SO_2NR'R", -SO_2R', nitro and trifluoromethyl; with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,


R_5 may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", nitro and trifluoromethyl, or R_5 together with one from among R_6 and R_7 forms a ring having 5 or 6 carbon atoms; with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms, and

R_6 and R_7, which may be identical or different each other, may be hydrogen, an alkyl group having from 1 to 5 carbon atoms, or together form a group C=O, or one from among R_6 and R_7, together with R_5, forms a ring having 5 or 6 carbon atoms,

with the proviso that when Y is -OH, A is different from an alkyl group having 1 carbon atom, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms, or alternatively at least one of the groups from R_1 to R_8 is different from hydrogen.

The claims defining the invention are as follows:

1. Compound of formula (I)



(I)

in which:

A is $-X_1-$ or $-X_1-OC(R_9)(R_{10})-$, in which

X_1 is an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and

R_9 and R_{10}, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

Y is OH

R_1 and R_2, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

R_3, R_4 and R_8, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", -CN, -CONR'R", $-SO_2NR'R"$, $-SO_2R'$, nitro and trifluoromethyl; with R' and R", which are identical or different to each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_5 is hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", nitro and trifluoromethyl, or R_5 together with one from among R_6 and R_7 forms a ring having 5 or 6 carbon atoms; with R' and R", which are identical or different to each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_6 and R_7, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms, or together form a group C=O, or one from among R_6 and R_7, together with R_5, forms a ring having 5 or 6 carbon atoms,

with the proviso that when Y is -OH, A is different from an alkyl group having 1 carbon atom, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms, or alternatively at least one of the groups from R_1 to R_8 is different from hydrogen.

2. Compound according to Claim 1, characterized in that X_1 is an alkyl group having from 1 to 3 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 3 carbon atoms or one or more alkoxy groups having 1 or 2 carbon atoms.

3. Compound according to Claim 1, characterized in that X_1 is chosen from the group comprising a group CH_2, a group CH_2CH_2 or a group $C(CH_3)_2$, and R_9 and R_{10}, which are identical or different to each other, are hydrogen or a CH_3 group.

4. Compound according to Claim 1, characterized in that residue A is chosen from the group comprising a group CH_2, a group CH_2CH_2, a group $C(CH_3)_2$, a group $CH_2CH_2OCH_2$, a group $CH_2CH_2OC(CH_3)_2$ and a group $CH_2CH_2CH_2OC(CH_3)_2$.

5. Compound according to Claim 1, characterized in that R_3, R_4 and R_8, which are identical or different to each other, are chosen from the group comprising a hydrogen atom, an alkyl group having from 1 to 3 carbon atoms, an alkoxy group having 1 or 2 carbon atoms, a Br, Cl or F atom, an OH group, a nitro group, a trifluoromethyl group or a group N(R')(R") or -N(R')COR", -CN, -CONR'R", $-SO_2NR'R"$, $-SO_2R'$, with R' and R", which are identical or different to each other, represented by a hydrogen atom and an alkyl group having from 1 to 3 carbon atoms.

6. Compound according to Claim 1, characterized in that R_5 is chosen from the group comprising a hydrogen atom, an alkyl group having from 1 to 3

carbon atoms, an alkoxy group having 1 or 2 carbon atoms, a halogen atom, an OH group, or R_5, together with one from among R_6 and R_7, forms a ring having 5 or 6 carbon atoms.

7. Compound according to Claim 1, characterized in that R_6 and R_7, which are identical or different to each other, are chosen from the group comprising a hydrogen atom, an alkyl group having from 1 to 3 carbon atoms, or together form a group C=O, or one from among R_6 and R_7, together with R_5, forms a ring having 5 or 6 carbon atoms.

8. Pharmaceutical composition comprising the compound of formula (I) according to any one of the preceding claims, or a pharmaceutically acceptable salt, ester or prodrug thereof, and at least one pharmaceutically acceptable vehicle.

9. Pharmaceutical composition according to Claim 8, characterized in that the said pharmaceutically acceptable salt is an addition salt with physiologically acceptable organic or mineral acids or bases.

10. Pharmaceutical composition according to Claim 9, characterized in that the said physiologically acceptable acids are chosen from the group comprising hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, ascorbic acid, benzoic acid, citric acid, fumaric acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-toluenesulfonic acid, benzenesulfonic acid, succinic acid, tannic acid and tartaric acid.

11. Pharmaceutical composition according to Claim 9, characterized in that the said physiologically acceptable bases are chosen from the group comprising ammonium hydroxide, calcium hydroxide, magnesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, N-methylglucamine, glucamine, glucosamine, histidine, N-(2-hydroxyethyl)piperidine, N-(2-hydroxyethyl)pyrrolidine, isopropylamine, lysine, methylglucamine, morpholine,


piperazine, piperidine, theobromine, triethylamine, trimethylamine, tripropylamine and tromethamine.

12. Pharmaceutical composition according to Claim 8, characterized in that the said pharmaceutically acceptable ester is formed with physiologically acceptable organic acids or alcohols.

13. Pharmaceutical composition according to any one of Claims 8 to 12, characterized in that the said composition contains a stereoisomer or an enantiomer of the compound of formula (I), or a pharmaceutically acceptable salt, ester or prodrug thereof, or a mixture thereof.

14. Pharmaceutical composition according to any one of Claims 8 to 13, characterized in that the said pharmaceutically acceptable vehicle is chosen from the group comprising glidants, binders, disintegrants, fillers, diluents, flavourings, colorants, fluidizers, lubricants, preserving agents, humectants, absorbents and sweeteners.

15. Use of a compound of formula (I)



(I)

in which:

A is $-X_1-$ or $-X_1-OC(R_9)(R_{10})-$, in which

X_1 is an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and

R_9 and R_{10}, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group

having from 1 to 3 carbon atoms,

Y is OH,

R_1 and R_2, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,


R_3, R_4 and R_8, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", -CN, -CONR'R", $-SO_2NR'R"$, $-SO_2R'$, nitro and trifluoromethyl; with R' and R", which are identical or different to each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_5 is hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", nitro and trifluoromethyl, or R_5 together with one from among R_6 and R_7 forms a ring having 5 or 6 carbon atoms; with R' and R", which are identical or different to each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_6 and R_7, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms, or together form a group C=O, or one from among R_6 and R_7, together with R_5, forms a ring having 5 or 6 carbon atoms,

for the preparation of a pharmaceutical composition for treating diseases based on the expression of CX3CR1 and p40 selected from the group comprising lupus nephritis, diabetic nephropathy, Crohn's disease, ulcerative colitis, coronary disorders, restenosis, myocardial infarction, angina, chronic degenerative inflammatory diseases, psoriasis, type II diabetes, tumours, and cancer.

16. Use of a compound of formula (I)



(I)

in which:

A is $-X_1-$ or $-X_1-OC(R_9)(R_{10})-$, in which

X_1 is an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and

R_9 and R_{10}, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

Y is OH,

R_1 and R_2, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

R_3, R_4 and R_8, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", -CN, -CONR'R", $-SO_2NR'R"$, $-SO_2R'$, nitro and trifluoromethyl; with R' and R", which are identical or different to each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_5 is hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", nitro and trifluoromethyl, or R_5 together with one from among R_6 and R_7 forms a ring having 5 or 6 carbon atoms; with R' and R", which are identical or different to each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_6 and R_7, which are identical or different to each other, are

hydrogen, an alkyl group having from 1 to 5 carbon atoms, or together form a group C=O, or one from among R_6 and R_7, together with R_5, forms a ring having 5 or 6 carbon atoms,

with the proviso that when Y is -OH, A is different from an alkyl group having 1 carbon atom, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms, or alternatively at least one of the groups from R_1 to R_8 is different from hydrogen,

for the preparation of a pharmaceutical composition for treating diseases based on the expression of MCP-1, CX3CR1 and p40.

17. Use according to Claim 16, characterized in that the said diseases based on the expression of MCP-1 and CX3CR1 are chosen from the group comprising articular diseases, renal diseases, cardiovascular diseases, metabolic syndrome, obesity, diabetes, insulin resistance and cancer.

18. Use according to Claim 16, characterized in that the said diseases based on the expression of MCP-1 are chosen from the group comprising rheumatoid arthritis, arthritis induced by viral infections, psoriatic arthritis, arthrosis, lupus nephritis, diabetic nephropathy, glomerulonephritis, polycystic kidney disease, interstitial lung disease, fibrosis, multiple sclerosis, Alzheimer's disease, HIV-associated dementia, atopic dermatitis, psoriasis, vasculitis, restenosis, atherosclerosis, myocardial infarction, angina, acute coronary diseases, adenomas, carcinomas and metastases, metabolic diseases and complications following surgical interventions.


19. Use according to Claim 16, characterized in that the said diseases based on the expression of CX3CR1 are chosen from the group comprising rheumatoid arthritis, lupus nephritis, diabetic nephropathy, Crohn's disease, ulcerative colitis, coronary disorders, restenosis, atherosclerosis, myocardial infarction, angina, and complications following surgical interventions.

20. Use according to Claim 16, characterized in that the said diseases based on the expression of p40 are chosen from the group comprising autoimmune diseases, chronic degenerative inflammatory diseases, and

cancer.

21. Use according to Claim 16, characterized in that the said diseases based on the expression of p40 are chosen from the group comprising rheumatoid arthritis, psoriasis, glomerulonephritis, diabetes, lupus erythematosus, diabetes, Crohn's disease, and tumours.

22. Method for treating or preventing diseases based on the expression of CX3CR1 and p40, selected from the group comprising lupus nephritis, diabetic nephropathy, Crohn's disease, ulcerative colitis, coronary disorders, restenosis, myocardial infarction, angina, chronic degenerative inflammatory diseases, psoriasis, type II diabetes, tumours, and cancer, characterized by the administration to a person in need thereof of an effective amount of a compound of formula (I):



(I)

in which:

A is $-X_1-$ or $-X_1-OC(R_9)(R_{10})-$, in which

X_1 is an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and

R_9 and R_{10}, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

Y is OH,

R_1 and R_2, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1


to 3 carbon atoms,

R_3, R_4 and R_8, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", -CN, -CONR'R", $-SO_2NR'R"$, $-SO_2R'$, nitro and trifluoromethyl; with R' and R", which are identical or different to each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_5 is hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", nitro and trifluoromethyl, or R_5 together with one from among R_6 and R_7 forms a ring having 5 or 6 carbon atoms; with R' and R", which are identical or different to each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms, and

R_6 and R_7, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms, or together form a group C=O, or one from among R_6 and R_7, together with R_5, forms a ring having 5 or 6 carbon atoms.

23. Method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40, characterized by the administration to a person in need thereof of an effective amount of a compound of formula (I):



(I)

in which:

A is $-X_1-$ or $-X_1-OC(R_9)(R_{10})-$, in which

X_1 is an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms,

and

R_9 and R_{10}, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

Y is OH

R_1 and R_2, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 3 carbon atoms,

R_3, R_4 and R_8, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", -CN, -CONR'R", $-SO_2NR'R"$, $-SO_2R'$, nitro and trifluoromethyl; with R' and R", which are identical or different to each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms,

R_5 is hydrogen, an alkyl group having from 1 to 5 carbon atoms, an alkoxy group having from 1 to 3 carbon atoms, a halogen atom, -OH, -N(R')(R"), -N(R')COR", nitro and trifluoromethyl, or R_5 together with one from among R_6 and R_7 forms a ring having 5 or 6 carbon atoms; with R' and R", which are identical or different to each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms, and

R_6 and R_7, which are identical or different to each other, are hydrogen, an alkyl group having from 1 to 5 carbon atoms, or together form a group C=O, or one from among R_6 and R_7, together with R_5, forms a ring having 5 or 6 carbon atoms,

with the proviso that when Y is -OH, A is different from an alkyl group having 1 carbon atom, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms, or alternatively at least one of the groups from R_1 to R_8 is different from hydrogen.